Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01757418 · ClinicalTrials.gov registry record · Phase 1
Intravenous Gammaglobulin for Sickle Cell Pain Crises
A Phase 1 study, sponsored by Albert Einstein College of Medicine.
- Completed
- Registry status
- Phase 1
- Development phase
- 300
- Enrollment target
NCT01757418 is a Phase 1 study that has completed, run by Albert Einstein College of Medicine. The registered enrollment target is 300 participants.
The verdict
NCT01757418, a Phase 1 study, has completed, sponsored by Albert Einstein College of Medicine.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 300 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether Intravenous Immunoglobulin (IVIG) is safe and effective in the acute treatment of pain crises in sickle cell disease. Funding Source: Food and Drug Administration (FDA), Office of Orphan Products Development (OOPD)
Interventions
- OTHER Normal saline
- DRUG Immune Globulin Intravenous (IVIG)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 300 participants |
| Start Date | 2008-11 |
| Est. Completion | 2024-12-18 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01757418
The ClinicalTrials.gov registry entry for NCT01757418 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 300 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Albert Einstein College of Medicine, which has 175 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Normal saline is the first listed.
NCT01757418 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01757418 about?
NCT01757418 is a clinical study titled "Intravenous Gammaglobulin for Sickle Cell Pain Crises". The purpose of this study is to determine whether Intravenous Immunoglobulin (IVIG) is safe and effective in the acute treatment of pain crises in sickle cell disease. Funding Source: Food and Drug Administration (FDA), Office of Orphan Products Development (OOPD)
What is the current status of trial NCT01757418?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 300 participants. The study started on 2008-11. Estimated completion is 2024-12-18.
What interventions are being tested in trial NCT01757418?
The interventions under investigation include: Normal saline (OTHER), Immune Globulin Intravenous (IVIG) (DRUG).
Who is sponsoring clinical trial NCT01757418?
This trial is sponsored by Albert Einstein College of Medicine, which has 175 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.